Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in participation at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects requiring withdrawal/discontinuation of study medication · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as adverse events requiring withdrawal of… compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in participation at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).
1 finding from 1 review
1Small sample size. · people with nerve damage (< 6 months' duration) in leprosy
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Improvement in sensory nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in improvement in sensory nerve function at 1 year compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
1 finding from 1 review
Ataxia rating score ICARS; range 0 to 100) · people with Friedreich ataxia
1 finding from 1 review
Ejection fraction · people with Friedreich ataxia
1 finding from 1 review
End‐diastolic interventricular septal thickness (IVSTd) Measured in mm · people with Friedreich ataxia
1 finding from 1 review
Left ventricular mass · people with Friedreich ataxia
1 finding from 1 review
Survival (not measured) · people with Friedreich ataxia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events · people with Friedreich ataxia
Antioxidant showed no clear difference in severe adverse events compared with placebo (low certainty).
1 finding from 1 review
Muscle strength · people with inclusion body myositis
2 findings from 1 review
Change in grip strength · people with inclusion body myositis
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review